PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17305573-9 2007 Recently, some COX-2 selective inhibitors have shown adverse cardiovascular side effects, resulting in the withdrawal of rofecoxib and valdecoxib from the market. rofecoxib 121-130 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 17612044-9 2007 At the turn of this century, there was enormous commercial development following the introduction of two new highly selective COX-2 inhibitors, known as coxibs (celecoxib and rofecoxib) which were claimed to have low GI side effects. rofecoxib 175-184 mitochondrially encoded cytochrome c oxidase II Homo sapiens 126-131 17504133-4 2007 This observation led to the development of COX-2 inhibitors or "coxibs" of which rofecoxib (Vioxx) characterized by a methylsulfone moiety and the sulfonamides celecoxib (Celebrex) and valdecoxib (Bextra). rofecoxib 81-90 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 17504133-4 2007 This observation led to the development of COX-2 inhibitors or "coxibs" of which rofecoxib (Vioxx) characterized by a methylsulfone moiety and the sulfonamides celecoxib (Celebrex) and valdecoxib (Bextra). rofecoxib 92-97 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 17222987-0 2007 A pathogenetic mechanism for COX-2 inhibitor-induced cardiovascular events proposed to be useful in structuring medical testimony in rofecoxib trials. rofecoxib 133-142 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 17555881-2 2007 The ideas about rofecoxib trials stem from a different paradigm to explain COX-2 inhibitor (coxib)-induced myocardial infarctions. rofecoxib 16-25 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 17030482-5 2006 Five of them show COX-2 inhibition close to that of nimesulide and rofecoxib, two reference COX-2 selective inhibitors. rofecoxib 67-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-97 17024689-8 2006 Recent users of COX-2 inhibitors had an increased risk of initiating antihypertensive therapy, regardless of specific drug (celecoxib adjusted OR = 1.7 (95%CI 1.3, 2.1); rofecoxib adjusted OR = 1.7 (95%CI 1.4, 1.9)). rofecoxib 170-179 mitochondrially encoded cytochrome c oxidase II Homo sapiens 16-21 17087947-3 2006 We conducted a randomized, placebo-controlled, double-blind trial to assess whether use of the selective COX-2 inhibitor rofecoxib would reduce the risk of colorectal adenomas. rofecoxib 121-130 mitochondrially encoded cytochrome c oxidase II Homo sapiens 105-110 16188370-1 2006 OBJECTIVE: To determine whether the cyclooxygenase (COX)-2 inhibitor rofecoxib increases the regression rates of cervical intraepithelial neoplasia (CIN) grade II and III. rofecoxib 69-78 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-58 17115981-3 2006 The Cox2 inhibitor, rofecoxib, has been reported effective in preventing perimenstrual migraine and in preventing recurrence of migraine. rofecoxib 20-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-8 16939524-1 2006 AIM: To examine the risk of angio-oedema among users of the newer cyclooxygenase (COX)-2 selective inhibitors celecoxib and rofecoxib and other non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) in a population-based case-control study. rofecoxib 124-133 mitochondrially encoded cytochrome c oxidase II Homo sapiens 66-88 16934053-0 2006 The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. rofecoxib 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 69-74 16934053-3 2006 AIMS & METHODS: We set out to examine the effect of the withdrawal of rofecoxib on the prescription of other COX-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) in Scotland, using a national prescription database. rofecoxib 74-83 mitochondrially encoded cytochrome c oxidase II Homo sapiens 113-118 16827136-0 2006 COX-2 inhibitors celecoxib and rofecoxib prevent oxidative DNA fragmentation. rofecoxib 31-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 16998619-1 2006 The objective of this study was to compare the pre-emptive analgesic effect of rofecoxib, a cyclooxygenase (COX)-2 inhibitor, with a more traditional and commonly used analgesic, ibuprofen, for mandibular third molar surgery, utilizing a prospective, randomized, double-blind, placebo-controlled clinical trial. rofecoxib 79-88 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-114 18690928-10 2006 Recent signals include amnesia and QTc prolongation with sibutramine; pain activation with sumatriptan; epistaxis with risperidone; psychiatric and visual disturbances with the COX-2 inhibitors celecoxib and rofecoxib and psoriasis with rofecoxib. rofecoxib 208-217 mitochondrially encoded cytochrome c oxidase II Homo sapiens 177-182 18690928-10 2006 Recent signals include amnesia and QTc prolongation with sibutramine; pain activation with sumatriptan; epistaxis with risperidone; psychiatric and visual disturbances with the COX-2 inhibitors celecoxib and rofecoxib and psoriasis with rofecoxib. rofecoxib 237-246 mitochondrially encoded cytochrome c oxidase II Homo sapiens 177-182 16519515-1 2006 The two cyclooxygenase enzymes, COX-1 and COX-2, are responsible for the committed step in prostaglandin biosynthesis and are the targets of the nonsteroidal antiinflammatory drugs aspirin and ibuprofen and the COX-2 selective inhibitors, Celebrex, Vioxx, and Bextra. rofecoxib 249-254 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 16519515-1 2006 The two cyclooxygenase enzymes, COX-1 and COX-2, are responsible for the committed step in prostaglandin biosynthesis and are the targets of the nonsteroidal antiinflammatory drugs aspirin and ibuprofen and the COX-2 selective inhibitors, Celebrex, Vioxx, and Bextra. rofecoxib 249-254 mitochondrially encoded cytochrome c oxidase II Homo sapiens 211-216 16412030-3 2006 There is a large amount of data that suggest traditional NSAIDs, as well as the new cyclooxygenase (COX)-2 selective inhibitors such as rofecoxib and celecoxib, have a role in the setting of primary and secondary prevention, and adjuvant therapy of both sporadic colorectal carcinoma and familial adenomatous polyposis. rofecoxib 136-145 mitochondrially encoded cytochrome c oxidase II Homo sapiens 84-106 16544582-2 2006 Rofecoxib (R) is a novel and specific COX-2 inhibitor which is caracterized by an highly selective COX-2 inhibition, and can be presumed as non cross-reactive with ASA. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 16529558-5 2006 Recent reports evidence that selective COX-2 inhibitor such as rofecoxib, can lead to thrombotic cardiovascular events through inhibition of prostacyclin formation in the infracted heart. rofecoxib 63-72 mitochondrially encoded cytochrome c oxidase II Homo sapiens 39-44 16529558-7 2006 Moreover, the COX-2/COX-1 selectivity ratio is vital in the design of COX-2 inhibitory drugs, as it is clear from rofecoxib, which is more than 50-fold COX-2 selective. rofecoxib 114-123 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 16529558-7 2006 Moreover, the COX-2/COX-1 selectivity ratio is vital in the design of COX-2 inhibitory drugs, as it is clear from rofecoxib, which is more than 50-fold COX-2 selective. rofecoxib 114-123 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 16529558-7 2006 Moreover, the COX-2/COX-1 selectivity ratio is vital in the design of COX-2 inhibitory drugs, as it is clear from rofecoxib, which is more than 50-fold COX-2 selective. rofecoxib 114-123 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 16544582-2 2006 Rofecoxib (R) is a novel and specific COX-2 inhibitor which is caracterized by an highly selective COX-2 inhibition, and can be presumed as non cross-reactive with ASA. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 99-104 16544582-16 2006 CONCLUSIONS: Despite ASA, Rofecoxib, largely due to its highly specificity for COX-2, proved a drug particularly safe in treating patients with AIA. rofecoxib 26-35 mitochondrially encoded cytochrome c oxidase II Homo sapiens 79-84 16249351-0 2005 Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. rofecoxib 101-110 mitochondrially encoded cytochrome c oxidase II Homo sapiens 85-90 16401468-4 2006 We examined the variability in degree and selectivity of COX-2 inhibition in humans in response to celecoxib and rofecoxib. rofecoxib 113-122 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 17154669-7 2006 Selective COX-2 inhibitors (celecoxib and rofecoxib [withdrawn from the market]) are well tolerated by almost all aspirin-sensitive asthmatic patients. rofecoxib 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 16599250-3 2006 OBJECTIVE: To assess the safety of rofecoxib, a selective COX-2 inhibitor, in ASA/NSAID-intolerant patients. rofecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 58-63 16091477-7 2005 Our data show that TT cells express both MDR1 and COX-2 and that rofecoxib, a selective COX-2 inhibitor, sensitizes TT cells to the cytotoxic effects of doxorubicin, reducing P-gp expression and function. rofecoxib 65-74 mitochondrially encoded cytochrome c oxidase II Homo sapiens 88-93 15998959-6 2005 RESULTS: Patients with a history of gastropathy were more likely to be prescribed COX-2 inhibitors than low-dose NSAIDs; the odds ratios were 1.73 (95%CI: 1.56-1.91) and 1.49 (1.33-1.66), respectively for celecoxib and rofecoxib. rofecoxib 219-228 mitochondrially encoded cytochrome c oxidase II Homo sapiens 82-87 16024204-8 2005 CONCLUSION: Proliferation of nasal polyps fibroblasts may be inhibited by Budesonide and a specific COX-2 inhibitor -Rofecoxib. rofecoxib 117-126 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 16083531-5 2005 Highly selective COX-2 inhibitors including celecoxib, rofecoxib, valdecoxib, lumiracoxib, and etoricoxib were developed with the hope of significantly reducing the serious gastrointestinal toxicities associated with chronic high-dose NSAID use. rofecoxib 55-64 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-22 15870389-10 2005 The order of potency of the COX-2 inhibitory activity of these drugs in RA synovial fibroblasts was celecoxib = SC-236 > rofecoxib > TT201 > TT101. rofecoxib 124-133 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 15494548-6 2005 Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib). rofecoxib 145-154 mitochondrially encoded cytochrome c oxidase II Homo sapiens 47-52 16088245-1 2005 AIMS: To present patients with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) after application of rofecoxib (Vioxx), a cyclo-oxygenase (COX) 2 inhibitor. rofecoxib 131-140 mitochondrially encoded cytochrome c oxidase II Homo sapiens 152-175 16088245-1 2005 AIMS: To present patients with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) after application of rofecoxib (Vioxx), a cyclo-oxygenase (COX) 2 inhibitor. rofecoxib 142-147 mitochondrially encoded cytochrome c oxidase II Homo sapiens 152-175 15934855-1 2005 Like all COX-2 inhibitors, rofecoxib has been developed based on the hypothesis that at comparable therapeutic efficacy, it would have a better safety and tolerability profile than conventional NSAIDs. rofecoxib 27-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 9-14 15899741-5 2005 However, only two of these reports involved renal transplant recipients, and in both, rofecoxib was the COX-2 inhibitor of concern. rofecoxib 86-95 mitochondrially encoded cytochrome c oxidase II Homo sapiens 104-109 15911218-4 2005 In contrast, naproxen (a non-selective NSAID) and rofecoxib (a selective inhibitor of COX-2), did not affect HO-1 expression. rofecoxib 50-59 mitochondrially encoded cytochrome c oxidase II Homo sapiens 86-91 15742005-2 2005 Previous studies with the selective COX-2 inhibitors, rofecoxib and celecoxib, have shown that they do not alter the progression of AD. rofecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 15981408-1 2005 (1) Evidence that the Cox-2 inhibitors have severe cardiovascular adverse effects continues to accumulate, including an increase in overall mortality in several trials of rofecoxib. rofecoxib 171-180 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 15999628-0 2005 [The medical reason for the prescription of COX-2 selective cyclo oxygenase inhibitor rofecoxib for the treatment of rheumatoid arthritis. rofecoxib 86-95 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 15834531-8 2005 Supposedly, the combination of tizanidine/rofecoxib used to be prescribed frequently for lumbar pain as selective cyclooxygenase-(COX-)2 inhibitors are visibly replacing the nonsteroidal antirheumatics due to their better side effect profile. rofecoxib 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 114-136 15977092-1 2005 This study was designed to test the hypothesis whether preemptive administration of rofecoxib, a novel selective COX-2 inhibitor, can prolong intraarticular bupivacaine analgesia after arthroscopic knee surgery. rofecoxib 84-93 mitochondrially encoded cytochrome c oxidase II Homo sapiens 113-118 15572651-2 2005 A number of COX-2 inhibitors, including celecoxib and rofecoxib, are already used in man for the treatment of inflammatory pain. rofecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 12-17 15494548-7 2005 The overall saturation binding affinity for COX-2 of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min). rofecoxib 121-130 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 17532719-1 2005 BACKGROUND: We investigated the potential interactions between esomeprazole and a non-selective nonsteroidal anti-inflammatory drug (NSAID; naproxen) or a cyclo-oxygenase (COX)-2-selective NSAID (rofecoxib) in healthy subjects. rofecoxib 196-205 mitochondrially encoded cytochrome c oxidase II Homo sapiens 155-178 15902994-0 2005 Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease. rofecoxib 51-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 15974940-5 2005 COX-2-selective inhibitors (Coxibs) such as celecoxib, rofecoxib or valdecoxib have been developed to achieve an equal relief of pain and inflammation as classical NSAIDs but without their risk of gastrointestinal side effects. rofecoxib 55-64 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 15974942-4 2005 The selective COX-2 inhibitor rofecoxib has no effect on PG production and does not induce damage in the stomach. rofecoxib 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 16119973-1 2005 BACKGROUND AND OBJECTIVES: Rofecoxib, a selective cyclo-oxygenase (COX)-2 inhibitor, was a widely marketed drug that was used for relief of pain and inflammation in arthritic conditions. rofecoxib 27-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 50-73 16180941-3 2005 OBJECTIVE: The objective of this study is to review cases of Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the FDA associated with the use of the selective COX-2 inhibitor NSAIDs celecoxib, rofecoxib and valdecoxib, and to compare reporting rates of the two conditions associated with these drugs to each other, meloxicam (an oxicam NSAID that came on the US market at a similar time) and the background incidence rate. rofecoxib 212-221 mitochondrially encoded cytochrome c oxidase II Homo sapiens 178-183 15733024-1 2005 The dramatic withdrawal of rofecoxib on 30 September 2004, along with safety concerns about other cyclo-oxygenase (COX)-2 inhibitors (especially valdecoxib), raises important issues for clinicians, pharmaceutical companies and regulatory authorities. rofecoxib 27-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 98-121 15663617-2 2005 Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, now being increasingly used in place of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-48 16035651-1 2005 The aim of the study was to investigate the effects of the cylooxygenase (COX)-2 specific inhibitor rofecoxib, on blood pressure (BP) and heart rate (HR) in patients with well-controlled hypertension and osteoarthritis via 24-h ambulatory monitoring. rofecoxib 100-109 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-80 16415488-7 2005 However, the reduced incidence of serious GI adverse effects compared to tNSAIDs demonstrated for 2 COX-2 inhibitors (e.g. rofecoxib and lumiracoxib) has been countered by an increased incidence of myocardial infarction and stroke detected in 5 placebo controlled trials involving the COX-2 inhibitors celecoxib, rofecoxib and valdecoxib. rofecoxib 123-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 15789535-5 2005 We report two cases of tubulointersticial nephritis confirmed by renal biopsy, associated with administration of the two Cox-2 inhibitors currently available on the market, celecoxib and rofecoxib. rofecoxib 187-196 mitochondrially encoded cytochrome c oxidase II Homo sapiens 121-126 16415488-7 2005 However, the reduced incidence of serious GI adverse effects compared to tNSAIDs demonstrated for 2 COX-2 inhibitors (e.g. rofecoxib and lumiracoxib) has been countered by an increased incidence of myocardial infarction and stroke detected in 5 placebo controlled trials involving the COX-2 inhibitors celecoxib, rofecoxib and valdecoxib. rofecoxib 123-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 285-290 15607056-0 2004 [Analysis of cost-minimization treatment with paracetamol or COX-2 inhibitors (rofecoxib) for pain from arthrosis of the knee or hip]. rofecoxib 79-88 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-66 15648986-3 2004 The results suggest statistically better pain relief for the selective COX-2 inhibitor rofecoxib compared to tenoxicam, a traditional NSAID. rofecoxib 87-96 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 16689132-3 2005 There are a lot data in the literature which suggest that selective COX-2 inhibitors (rofecoxib and celecoxib) produce the similar effects on the kidney as traditional nonsteroidal anti-inflammatory drugs (inhibitors of COX-1 and COX-2). rofecoxib 86-95 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-73 16689132-3 2005 There are a lot data in the literature which suggest that selective COX-2 inhibitors (rofecoxib and celecoxib) produce the similar effects on the kidney as traditional nonsteroidal anti-inflammatory drugs (inhibitors of COX-1 and COX-2). rofecoxib 86-95 mitochondrially encoded cytochrome c oxidase II Homo sapiens 230-235 15179440-0 2004 Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). rofecoxib 96-105 mitochondrially encoded cytochrome c oxidase II Homo sapiens 69-74 15534440-7 2004 Current research is addressing the COX-2 inhibitor, rofecoxib, which has theoretical advantages with respect to fetal safety. rofecoxib 52-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-40 15179440-5 2004 Among them, 39 patients received placebo, and 37 received COX-2-selective inhibitor rofecoxib 25 mg daily for a period of 4 weeks. rofecoxib 84-93 mitochondrially encoded cytochrome c oxidase II Homo sapiens 58-63 15179440-13 2004 CONCLUSION: Our data suggest that COX-2-selective inhibitor rofecoxib is an effective medication in prevention of HO after SCI. rofecoxib 60-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 34-39 15623263-0 2004 COX-2 inhibitor use after Vioxx: careful balance or end of the rope? rofecoxib 26-31 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 15494133-6 2004 Levels of PGE-M in healthy humans are suppressed significantly not only by the nonselective COX inhibitor ibuprofen but also by the COX-2 selective inhibitor rofecoxib, suggesting that the majority of PGE2 formed in vivo is derived from COX-2. rofecoxib 158-167 mitochondrially encoded cytochrome c oxidase II Homo sapiens 132-137 15494133-6 2004 Levels of PGE-M in healthy humans are suppressed significantly not only by the nonselective COX inhibitor ibuprofen but also by the COX-2 selective inhibitor rofecoxib, suggesting that the majority of PGE2 formed in vivo is derived from COX-2. rofecoxib 158-167 mitochondrially encoded cytochrome c oxidase II Homo sapiens 237-242 15865061-1 2004 The selective inhibition of COX-2 isozymes should lead to a new generation of NSAIDs with significantly reduced side effects; e.g. celecoxib (Celebrex) and rofecoxib (Vioxx). rofecoxib 156-165 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 15570733-0 2004 The Vioxx withdrawal: latest in the COX-2 controversies. rofecoxib 4-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 15570734-0 2004 A world without Vioxx: to COX-2 or not to COX-2? rofecoxib 16-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 15570734-0 2004 A world without Vioxx: to COX-2 or not to COX-2? rofecoxib 16-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 15865061-1 2004 The selective inhibition of COX-2 isozymes should lead to a new generation of NSAIDs with significantly reduced side effects; e.g. celecoxib (Celebrex) and rofecoxib (Vioxx). rofecoxib 167-172 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 15865061-3 2004 Although X-ray structures of COX-2 complexed with a small number of ligands are available, experimental data are missing for two well-known selective COX-2 inhibitors (rofecoxib and nimesulide) and docking results reported are controversial. rofecoxib 168-177 mitochondrially encoded cytochrome c oxidase II Homo sapiens 150-155 15576013-4 2004 Rofecoxib is the most specific COX-2 inhibitor among the first generation of the class, i.e., negligible COX-1 inhibitory effect. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 31-36 15548128-0 2004 Market withdrawal of Vioxx: is it time to rethink the use of COX-2 inhibitors? rofecoxib 21-26 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-66 15151910-3 2004 We report a case of a 72-year-old woman who presented with a 6-week history of profound confusion whilst being treated with rofecoxib, a COX-2 inhibitor. rofecoxib 124-133 mitochondrially encoded cytochrome c oxidase II Homo sapiens 137-142 15486258-1 2004 Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. rofecoxib 14-19 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 15355480-0 2004 Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. rofecoxib 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 15521372-8 2004 The SBPCOCs with the selective COX-2 inhibitors celecoxib and rofecoxib were well tolerated in all cases. rofecoxib 62-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 31-36 15462687-2 2004 Rofecoxib, a COX-2 specific inhibitor, was developed to provide similar efficacy and less GI toxicity than NSAIDs. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 15623076-1 2004 Rofecoxib (Vioxx), the first COX-2 selective non-steroidal anti-inflammatory drug (NSAID), was recently withdrawn by Merck Sharp & Dohme. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 15623076-1 2004 Rofecoxib (Vioxx), the first COX-2 selective non-steroidal anti-inflammatory drug (NSAID), was recently withdrawn by Merck Sharp & Dohme. rofecoxib 11-16 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 15561649-2 2004 The COX-2SIs rofecoxib and celecoxib have been shown to be as effective as traditional NSAADs for pain relief, but with an improved GI safety profile. rofecoxib 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 15194006-0 2004 Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. rofecoxib 56-65 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 15200656-1 2004 BACKGROUND: Rofecoxib is a selective COX-2 inhibitor that does not interfere with platelet function and is associated with fewer bleeding complications than other nonsteroidal anti-inflammatory agents (NSAIDs). rofecoxib 12-21 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 15145696-3 2004 We hypothesized that a selective and commercially available COX-2 inhibitor, rofecoxib (Vioxx), would inhibit growth of Barrett"s adenocarcinoma and squamous cell carcinoma of the esophagus by apoptotic pathways. rofecoxib 77-86 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 15232052-0 2004 Delirium From the COX-2 inhibitor refecoxib. rofecoxib 34-43 mitochondrially encoded cytochrome c oxidase II Homo sapiens 18-23 15145696-3 2004 We hypothesized that a selective and commercially available COX-2 inhibitor, rofecoxib (Vioxx), would inhibit growth of Barrett"s adenocarcinoma and squamous cell carcinoma of the esophagus by apoptotic pathways. rofecoxib 88-93 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 15117884-2 2004 Selective inhibitors of COX-2, such as celecoxib, etoricoxib, lumiracoxib, rofecoxib, and valdecoxib have been developed and the greatest recent growth in our knowledge in this area has been come from the clinical use of these compounds. rofecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 15136366-0 2004 Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 15136366-2 2004 AIM: To evaluate whether patients with ACS treated with rofecoxib, a COX-2 inhibitor, will have reduced CRP, IL-6, and soluble tumor necrotic factor receptor-1 (sTNF-R1) levels and improved endothelial function. rofecoxib 56-65 mitochondrially encoded cytochrome c oxidase II Homo sapiens 69-74 15329003-3 2004 OBJECTIVE: The aim of this study was to evaluate the tolerability of three COX-2 inhibitors (meloxicam, celecoxib and rofecoxib) in subjects with previous pseudoallergic respiratory and cutaneous reactions to NSAIDs. rofecoxib 118-127 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 15133778-9 2004 CONCLUSIONS: Patients on the COX-2 specific inhibitors (celecoxib and rofecoxib) were significantly less likely to switch their therapy than patients on NS-NSAIDS (ibuprofen, naproxen and diclofenac). rofecoxib 70-79 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 15182793-1 2004 OBJECTIVES: Two selective COX2 inhibitors, rofecoxib and celecoxib, were introduced on the French market in 2000. rofecoxib 43-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-30 14977803-3 2004 This study tested the hypothesis that the COX-2-selective inhibitor rofecoxib has less influence on platelet function than the NSAID diclofenac in gynaecological surgery. rofecoxib 68-77 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 14760808-12 2004 Among the COX-2-specific inhibitors, celecoxib has a longer survival time than rofecoxib. rofecoxib 79-88 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 15086362-3 2004 OBJECTIVES: To study the effects of COX2 inhibitor rofecoxib on platelet function using in vitro tests. rofecoxib 51-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-40 15050982-4 2004 In vivo studies have found the specific COX-2 inhibitors rofecoxib (Vioxx) and valdecoxib (Bextra) effective in treatment of primary dysmenorrhea in women >or=18 years. rofecoxib 57-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 15050982-4 2004 In vivo studies have found the specific COX-2 inhibitors rofecoxib (Vioxx) and valdecoxib (Bextra) effective in treatment of primary dysmenorrhea in women >or=18 years. rofecoxib 68-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 15082814-0 2004 Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib. rofecoxib 123-132 mitochondrially encoded cytochrome c oxidase II Homo sapiens 107-112 15082814-3 2004 This marketing continues even though a pivotal safety study with one of the COX-2 inhibitors, rofecoxib, showed a significant increase in myocardial infarction with rofecoxib use compared with a traditional anti-inflammatory drug. rofecoxib 94-103 mitochondrially encoded cytochrome c oxidase II Homo sapiens 76-81 15082814-3 2004 This marketing continues even though a pivotal safety study with one of the COX-2 inhibitors, rofecoxib, showed a significant increase in myocardial infarction with rofecoxib use compared with a traditional anti-inflammatory drug. rofecoxib 165-174 mitochondrially encoded cytochrome c oxidase II Homo sapiens 76-81 14713756-7 2004 Selective COX-2 inhibitors are currently under study to evaluate their potential roles in preventing prostate cancer in high-risk patients (rofecoxib) or the recurrence of bladder cancer (celecoxib). rofecoxib 140-149 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 17516707-6 2004 In the present study we investigated the treatment of patients with osteoarthritis with lornoxicam in comparison with treatment with the selective COX-2 inhibitor rofecoxib. rofecoxib 163-172 mitochondrially encoded cytochrome c oxidase II Homo sapiens 147-152 16146090-1 2004 Clinical and experimental studies have shown that renal and cardiovascular effects of most selective COX-2 inhibitors (rofecoxib, celecoxib) are similar to other traditional NSAIDs (dual COX inhibitors). rofecoxib 119-128 mitochondrially encoded cytochrome c oxidase II Homo sapiens 101-106 14504873-0 2003 A comparative study of the effect of rofecoxib (a COX 2 inhibitor) and naproxen sodium on analgesic requirements after abdominal hysterectomy. rofecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 50-55 14756580-5 2004 This review focuses on the NSAID rofecoxib, one of the selective cyclo-oxygenase (COX)-2 inhibitors, which are claimed to be as effective as nonselective NSAIDs with better gastrointestinal tolerability. rofecoxib 33-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 65-88 14655004-2 2003 Currently, there are four selective COX-2 inhibitors available in Germany: celecoxib, rofecoxib, valdecoxib and parecoxib. rofecoxib 86-95 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 14585914-5 2003 Results demonstrate that the median duration of treatment was longer among patients initially prescribed COX-2-specific inhibitors (30 days and 23 days for celecoxib and rofecoxib respectively) than in those prescribed non-selective NSAIDs (10 days). rofecoxib 170-179 mitochondrially encoded cytochrome c oxidase II Homo sapiens 105-110 14530224-2 2003 Unlike NSAIDs, rofecoxib targets only the COX-2 isoform. rofecoxib 15-24 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 14965322-6 2004 Etoricoxib shows only a slightly improved COX-2 selectivity than rofecoxib, a highly selective COX-2 inhibitor that has been reported to halve the incidence of serious gastrointestinal toxicity compared to nonselective nonsteroidal antiinflammatory drugs (NSAIDs). rofecoxib 65-74 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 12902855-6 2003 Two specific COX-2 inhibitors, namely, rofecoxib (Vioxx) and celecoxib (Celebrex), both oral agents and FDA approved, have been shown preclinically and clinically to have efficacy comparable to that of NSAIDs for relief of pain and inflammation in osteoarthritis, with decreased risk of gastrointestinal damage. rofecoxib 39-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 14627347-1 2003 The long-term (mean of 16.4 +/- 4.2 months) efficacy and safety of rofecoxib (a specific COX-2 inhibitor) in maintaining the colon free of polyps in familial polyposis patients was assessed. rofecoxib 67-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 89-94 12975714-7 2003 The average total daily dose of COX-2 inhibitor was 219.2 mg for celecoxib and 25.23 mg for rofecoxib. rofecoxib 92-101 mitochondrially encoded cytochrome c oxidase II Homo sapiens 32-37 14524083-0 2003 [Selective COX 2 inhibitor rofecoxib. rofecoxib 27-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 11-16 12902855-6 2003 Two specific COX-2 inhibitors, namely, rofecoxib (Vioxx) and celecoxib (Celebrex), both oral agents and FDA approved, have been shown preclinically and clinically to have efficacy comparable to that of NSAIDs for relief of pain and inflammation in osteoarthritis, with decreased risk of gastrointestinal damage. rofecoxib 50-55 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 12890715-5 2003 Treating HUVEC with selective COX-2 inhibitors, celecoxib and rofecoxib, caused an approximately 70% reversion of antiadhesive effect of aspirin. rofecoxib 62-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 12859668-3 2003 The late increase in PGE2 levels (24 h) was more potently reduced by the highly selective COX-2 inhibitor rofecoxib (20 mg/kg) relative to the COX-1 inhibitor valeryl salicylate (20 mg/kg). rofecoxib 106-115 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 15071803-0 2003 High performance liquid chromatographic determination of cox-2 inhibitor rofecoxib in human plasma. rofecoxib 73-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 12859668-5 2003 Post-ischemia treatment with rofecoxib (starting 6 h after restoration of blood flow) significantly reduced measures of oxidative damage (glutathione depletion and lipid peroxidation) seen at 48 h after the initial ischemic episode, indicating that the late increase in COX-2 activity is involved in the delayed occurrence of oxidative damage in the hippocampus after global ischemia. rofecoxib 29-38 mitochondrially encoded cytochrome c oxidase II Homo sapiens 270-275 12859668-6 2003 Interestingly, either selective inhibition of COX-2 with rofecoxib or inhibition of COX-1 with valeryl salicylate significantly increased the number of healthy neurons in the hippocampal CA1 sector even when the treatment began 6 h after ischemia. rofecoxib 57-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 46-51 12818939-1 2003 UNLABELLED: The goal of our study was to evaluate the analgesic efficacy and safety of administering rofecoxib (1 mg/kg), a cyclo-oxygenase (COX)-2 selective nonsteroidal antiinflammatory drug, before pediatric tonsillectomy. rofecoxib 101-110 mitochondrially encoded cytochrome c oxidase II Homo sapiens 124-147 12845388-1 2003 Rofecoxib (VIOXX, Merck & Co., West Point, PA) is a COX-2-selective inhibitor that combines anti-inflammatory and analgesic efficacy with improved gastrointestinal (GI) safety. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 56-61 12845388-1 2003 Rofecoxib (VIOXX, Merck & Co., West Point, PA) is a COX-2-selective inhibitor that combines anti-inflammatory and analgesic efficacy with improved gastrointestinal (GI) safety. rofecoxib 11-16 mitochondrially encoded cytochrome c oxidase II Homo sapiens 56-61 12557133-9 2003 Serious lower GI events were 54% lower with the use of the selective COX-2 inhibitor rofecoxib. rofecoxib 85-94 mitochondrially encoded cytochrome c oxidase II Homo sapiens 69-74 14592550-8 2003 On the other hand, the selective inhibitor of COX-2 (rofecoxib) as well as the inhibitor of cytochrome P450-dependent monoxygenase (17-ODYA) were ineffective. rofecoxib 53-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 46-51 12783912-2 2003 OBJECTIVE: To determine whether treatment with a selective cyclooxygenase (COX) -2 inhibitor (rofecoxib) or a traditional nonselective NSAID (naproxen) slows cognitive decline in patients with mild-to-moderate AD. rofecoxib 94-103 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-82 12740337-1 2003 BACKGROUND: Previous studies in patients with osteoarthritis have suggested that the selective cyclooxygenase (COX)-2 inhibitor rofecoxib results in less gastrointestinal damage than non-selective non-steroidal antiinflammatory drugs (NSAIDs). rofecoxib 128-137 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-117 14552704-2 2003 Rofecoxib and celecoxib are the first selective COX-2 inhibitors approved by the FDA and EMEA for the treatment of rheumatoid arthritis (RA), osteoarthritis (OA) and for relief of acute pain. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 15199473-3 2003 Aspirin is less effective in inhibiting COX-2 activity, whereas celecoxib and rofecoxib selectively inhibit COX-2 activity as they contain a side chain to anchor to the side pocket of COX-2 substrate channel. rofecoxib 78-87 mitochondrially encoded cytochrome c oxidase II Homo sapiens 108-113 15199473-3 2003 Aspirin is less effective in inhibiting COX-2 activity, whereas celecoxib and rofecoxib selectively inhibit COX-2 activity as they contain a side chain to anchor to the side pocket of COX-2 substrate channel. rofecoxib 78-87 mitochondrially encoded cytochrome c oxidase II Homo sapiens 108-113 12723742-3 2003 COX-2 inhibitors such as celecoxib and rofecoxib appear to be as effective as non-selective NSAIDs in the treatment of chronic inflammatory disease but their analgesic efficacy and their safety at the higher doses required for analgesia are less certain. rofecoxib 39-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 12723745-4 2003 Of the cyclo-oxygenase (COX)-2 selective NSAIDs, rofecoxib is associated with a lower risk of gastrointestinal toxicity but there is uncertainty about the long-term risk associated with celecoxib. rofecoxib 49-58 mitochondrially encoded cytochrome c oxidase II Homo sapiens 7-30 12868201-3 2003 Slow, time-dependent, irreversible, highly selective inhibitors of COX-2 such as celecoxib, etoricoxib, rofecoxib and valdecoxib, so-called coxibs, are a new group of drugs widely used in rheumatology as well as in other fields of medicine. rofecoxib 104-113 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 12604692-1 2003 Rofecoxib is a selective cyclooxygenase (COX)-2 inhibitor approved for the treatment of pain and inflammation in rheumatoid and osteoarthritis. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-47 12490541-7 2003 In a clinical study, we analyzed the effect of a selective COX-2 inhibitor, Rofecoxib, on the migration of monocytes derived from cancer patients. rofecoxib 76-85 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-64 12906745-8 2003 Emerging evidence suggests that rofecoxib may also find potential use as supportive therapy in various pathophysiologic conditions like Alzheimer"s disease, and in various malignant tumours and polyps, where COX-2 is overly expressed. rofecoxib 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 208-213 12910695-12 2003 Rofecoxib down-regulated the expression of COX-2 and PCNA of SGC7901 cell, both in vitro and in vivo. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 12782016-3 2003 We demonstrate that rofecoxib, a selective COX-2 inhibitor, acts directly on human dermal microvascular ECs (HMVECs) to inhibit their chemotactic and tube forming ability. rofecoxib 20-29 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 12941996-4 2003 These studies evaluated the efficacy and tolerability of rofecoxib, a selective COX-2 inhibitor, in the treatment of chronic low back pain. rofecoxib 57-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 80-85 12668898-5 2003 Furthermore, for patients with AERD and chronic urticaria, they can be given the new selective COX-2 inhibitors (rofecoxib and celecoxib) without any cross-reactivity. rofecoxib 113-122 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 12749519-3 2003 OBJECTIVE: The objective of this analysis was to estimate the COX-2 specific inhibitor medication costs, in addition to the costs of drugs and physicians" fees, for BP destabilization and clinically significant edema associated with the use of rofecoxib 25 mg QD and celecoxib 200 mg QD in patients with OA and hypertension in a Medicare Choice population (aged > or = 65 years). rofecoxib 244-253 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 12583353-0 2003 Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib. rofecoxib 105-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 12217369-1 2002 A group of isomers possessing a 2-, 3-, or 4-acetoxy moiety on the 3-phenyl substituent of rofecoxib were synthesized that exhibit highly potent, and selective, COX-2 inhibitory activity that have the potential to acetylate the COX-2 isozyme. rofecoxib 91-100 mitochondrially encoded cytochrome c oxidase II Homo sapiens 161-166 12816152-4 2003 The goal of our study was to estimate the frequency of intolerance reactions due to ingestion of the two newly approved selective COX-2 inhibitors, rofecoxib or celecoxib. rofecoxib 148-157 mitochondrially encoded cytochrome c oxidase II Homo sapiens 130-135 12522725-25 2003 It consists of the simultaneous administration of low-dose ketamine, co-administration of an alpha 2-agonist, and the administration of a selective COX-2 inhibitor (refecoxib, parecoxib) respectively. rofecoxib 165-174 mitochondrially encoded cytochrome c oxidase II Homo sapiens 148-153 12629931-1 2003 The discovery of the isoenzymes cyclooxygenase-(COX-) 1 and COX-2 led to the development of newer nonsteroidal anti-inflammatory drugs (NSAIDs) designed to block COX-2, such as rofecoxib, celecoxib, and valdecoxib. rofecoxib 177-186 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 12629931-1 2003 The discovery of the isoenzymes cyclooxygenase-(COX-) 1 and COX-2 led to the development of newer nonsteroidal anti-inflammatory drugs (NSAIDs) designed to block COX-2, such as rofecoxib, celecoxib, and valdecoxib. rofecoxib 177-186 mitochondrially encoded cytochrome c oxidase II Homo sapiens 162-167 12705064-4 2003 Because of their better gastrointestinal risk profile, the newly developed selective COX-2 inhibitors celecoxib and rofecoxib are discussed as cost-effective alternatives to common NSAIDs. rofecoxib 116-125 mitochondrially encoded cytochrome c oxidase II Homo sapiens 85-90 12445672-8 2003 Vioxx showed specific COX-2 inhibition by 71%. rofecoxib 0-5 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 12410658-0 2002 Factor-sparing use of the COX-2 inhibitor rofecoxib in haemophilic arthropathy. rofecoxib 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 12406411-0 2002 [Economic evaluation of a new selective COX-2 NSAID, rofecoxib, in a real practice context]. rofecoxib 53-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 12217369-1 2002 A group of isomers possessing a 2-, 3-, or 4-acetoxy moiety on the 3-phenyl substituent of rofecoxib were synthesized that exhibit highly potent, and selective, COX-2 inhibitory activity that have the potential to acetylate the COX-2 isozyme. rofecoxib 91-100 mitochondrially encoded cytochrome c oxidase II Homo sapiens 228-233 12455713-7 2002 Therefore, rofecoxib and celecoxib, selective inhibitors of COX-2, at least in vitro, were introduced. rofecoxib 11-20 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 12395741-2 2002 ULCER COMPLICATIONS: The probability of developing a symptomatic, uncomplicated or complicated (perforation, gastric outlet obstruction, bleeding) gastroduodenal ulcer is significantly lower with a COX-2 selective inhibitor (Celecoxib, rofecoxib) than with a traditional NSAIDs, with a reduction in absolute risk of around 1-1.5 for 100 patient-years in clinical trials. rofecoxib 236-245 mitochondrially encoded cytochrome c oxidase II Homo sapiens 198-203 12389882-5 2002 We describe the case of a 71-year-old woman who developed acute renal failure after receiving a 50-mg dose of the selective COX-2 inhibitor rofecoxib. rofecoxib 140-149 mitochondrially encoded cytochrome c oxidase II Homo sapiens 124-129 12703120-3 2002 Two NSAIDs (celecoxib and rofecoxib) COX-2 specific inhibitors had considerably lower ulcerogenic rates and lower serious gastro-intestinal side effects when compared with other NSAIDs used in rheumatoid arthritis and osteoarthritis. rofecoxib 26-35 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 12198983-7 2002 RESULTS: The findings of this literature review show that the COX-2-selective inhibitor rofecoxib is no more effective than conventional, nonselective, nonsteroidal anti-inflammatory drugs, or NSAIDs, for the relief of postoperative dental pain. rofecoxib 88-97 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 12220285-5 2002 Rofecoxib is a selective COX-2 inhibitor that has been shown to increase sodium reabsorption in the kidney via effects on prostaglandin E2 and the renal vasculature. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-30 12141411-4 2002 Rofecoxib, a specific COX 2 inhibitor, promptly elevated serum potassium concentration with normalization of plasma aldosterone and near normalization of renin without a change in serum magnesium. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 12204486-7 2002 Recent studies have demonstrated that the COX-2 inhibitor rofecoxib significantly improves quality of life in patients with osteoarthritis and chronic, lower back pain. rofecoxib 58-67 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 12113843-3 2002 Five days before admission, rofecoxib, a new selective COX-2 inhibitor nonsteroidal anti-inflammatory drug (NSAID), was added for leg pain. rofecoxib 28-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-60 12100094-4 2002 Rofecoxib is a member of a new class of NSAIDs, which selectively inhibits the COX-2 enzyme and therefore is associated with a lower risk of gastrointestinal side-effects; the drug has a long plasma half-life (17 h). rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 79-84 12126328-1 2002 Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). rofecoxib 39-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 12126328-1 2002 Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). rofecoxib 50-55 mitochondrially encoded cytochrome c oxidase II Homo sapiens 22-27 12065343-4 2002 OBJECTIVE: The purpose of this study was to demonstrate that rofecoxib, a specific inhibitor of COX-2, does not cause asthmatic attacks in patients with ASA and/or other NSAID-induced asthma. rofecoxib 61-70 mitochondrially encoded cytochrome c oxidase II Homo sapiens 96-101 11992745-4 2002 It is assumed therefore that the COX-2-selective inhibitors, rofecoxib and celecoxib, would have an effect on renal function similar to that of nonselective NSAIDs. rofecoxib 61-70 mitochondrially encoded cytochrome c oxidase II Homo sapiens 33-38 11898894-2 2002 Rofecoxib, a COX-2-specific NSAID, does not inhibit the COX-1 enzyme, thereby decreasing the potential for gastrointestinal-related adverse effects. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 11909557-8 2002 Apparent differences between the COX-2 inhibitors celecoxib and rofecoxib may be functions of differences in study population susceptibilities to NSAID-mediated hypertensive effects. rofecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 33-38 11940070-2 2002 OBJECTIVE: To assess the tolerability of rofecoxib, a drug that specifically inhibits COX-2, in a group of NSAID-sensitive patients. rofecoxib 41-50 mitochondrially encoded cytochrome c oxidase II Homo sapiens 86-91 11789101-9 2001 We have now been studying the COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). rofecoxib 47-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 12086291-9 2002 Clinical studies of the COX-2-selective inhibitors rofecoxib and celecoxib have demonstrated efficacy equivalent to nonselective NSAIDs with lower rates of GI side effects (for example, incidence of endoscopic ulcers equivalent to placebo). rofecoxib 51-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 12017215-2 2002 Rofecoxib, an agent that selectively inhibits COX-2, has been shown to provide equivalent anti-inflammatory and analgesic efficacy to comparator non-selective NSAIDs in osteoarthritis (OA) and other pain models with a significant improvement in gastrointestinal (GI) safety and tolerability. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 46-51 11819916-12 2001 Excepting two compounds recently marketed (celecoxib, rofecoxib) selective for COX-2, all other NSAID have few or no selective properties. rofecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 79-84 11945113-5 2002 The recent introduction of selective COX-2 inhibitors, celecoxib and rofecoxib, appear to induce less gastrointestinal morbidity. rofecoxib 69-78 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 11866383-1 2002 Rofecoxib is a selective cyclooxygenase (COX)-2 inhibitor that is approved for the treatment of acute pain and osteoarthritis in adults. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-47 11789101-9 2001 We have now been studying the COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). rofecoxib 58-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-35 11742186-4 2001 The COX-2 selective NSAID, rofecoxib, is in comparison with naproxen, a non-selective NSAID, associated with fewer clinically important upper gastrointestinal events. rofecoxib 27-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 11717412-2 2001 However, clinical studies have shown that the Cox-2 selective drugs (or coxibs) rofecoxib and etoricoxib, at therapeutic doses, do not interfere with the antiplatelet effect of aspirin, in contrast to ibuprofen. rofecoxib 80-89 mitochondrially encoded cytochrome c oxidase II Homo sapiens 46-51 11695246-2 2001 The cyclooxygenase (COX)-2 selective inhibitors celecoxib and rofecoxib have been found to be more effective than placebo and comparably effective to nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of patients with osteoarthritis and rheumatoid arthritis. rofecoxib 62-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-26 11696466-2 2001 Among the randomized, controlled trials with the COX-2 inhibitor rofecoxib, one study demonstrated a significant difference between rofecoxib and its NSAID comparator (naproxen) in the risk of CV thrombotic events. rofecoxib 132-141 mitochondrially encoded cytochrome c oxidase II Homo sapiens 49-54 11695253-6 2001 Following the discovery of the two differentially distributed and regulated COXs, two non-acidic COX-2-selective compounds--celecoxib and rofecoxib--were introduced. rofecoxib 138-147 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 11695246-3 2001 Two large outcome studies, the Celecoxib Long-term Arthritis Safety Study (CLASS) and Vioxx Gastrointestinal Outcomes Research (VIGOR) trial, were conducted to test the hypothesis that patients receiving a COX-2 selective inhibitor would have significantly fewer clinically important upper gastrointestinal events than patients taking nonselective NSAIDs. rofecoxib 86-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 206-211 11695253-11 2001 We therefore propose that a drug combining the pharmacokinetic characteristics of, for example, ibuprofen with the COX-2 selectivity of rofecoxib is likely to be a superior anti-inflammatory analgesic. rofecoxib 136-145 mitochondrially encoded cytochrome c oxidase II Homo sapiens 115-120 11570615-6 2001 Reaction rates for COX-2 inhibitors were 21.3% for nimesulide, 17.3% for meloxicam, 33.3% for celecoxib, and 3.0% for rofecoxib. rofecoxib 118-127 mitochondrially encoded cytochrome c oxidase II Homo sapiens 19-24 11586092-6 2001 Two specific COX-2 inhibitors, namely rofecoxib (Vioxx) and celecoxib (Celebrex), both oral agents and U.S. Food and Drug Administration approved, have been shown preclinically and clinically to have efficacy comparable to that of NSAIDs for relief of pain and inflammation in osteoarthritis, with decreased risk of gastrointestinal damage. rofecoxib 38-47 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 11586092-6 2001 Two specific COX-2 inhibitors, namely rofecoxib (Vioxx) and celecoxib (Celebrex), both oral agents and U.S. Food and Drug Administration approved, have been shown preclinically and clinically to have efficacy comparable to that of NSAIDs for relief of pain and inflammation in osteoarthritis, with decreased risk of gastrointestinal damage. rofecoxib 49-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 11706832-0 2001 Discussion on rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. rofecoxib 14-23 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 11601668-2 2001 Cyclooxygenase (COX)-2 inhibitors (coxibs) rofecoxib and celecoxib are highly selective inhibitors of COX-2, differentiating them from nonselective NSAIDs, which substantially inhibit both COX-1 and COX-2. rofecoxib 43-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 102-107 11601668-2 2001 Cyclooxygenase (COX)-2 inhibitors (coxibs) rofecoxib and celecoxib are highly selective inhibitors of COX-2, differentiating them from nonselective NSAIDs, which substantially inhibit both COX-1 and COX-2. rofecoxib 43-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 199-204 11570615-7 2001 CONCLUSIONS: Some COX-2 inhibitors, such as rofecoxib, are relatively safe in NSAID-sensitive patients with urticaria or angioedema. rofecoxib 44-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 18-23 11589261-4 2001 OBJECTIVE: This study sought to compare renal safety signals between the COX-2-specific inhibitors rofecoxib and celecoxib, based on spontaneous reports of adverse drug reactions (ADRs) in the World Health Organization/Uppsala Monitoring Centre (WHO/UMC) safety database through the end of the second quarter 2000. rofecoxib 99-108 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-78 11425807-0 2001 Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. rofecoxib 86-95 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 11571832-10 2001 In search for selective blockers of COX-2, celecoxib and rofecoxib were developed which have an analgetic and antirheumatic potency similar to that of conventional NSAIDs but are associated with significantly fewer adverse gastroduodenal events. rofecoxib 57-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 11425807-2 2001 METHODS: Thirteen healthy women, 30-40 years of age, without hormonal treatment and with regular menstrual cycles (27-34 days), were given the selective COX-2 inhibitor rofecoxib (n = 6) or placebo (n = 7) in a random double-blind fashion. rofecoxib 169-178 mitochondrially encoded cytochrome c oxidase II Homo sapiens 153-158 11503270-4 2001 Selective COX-2 inhibitors i.e. meloxicam, nimesulid, etodolac or highly selective COX-2 inhibitors i.e. celecoxib, rofecoxib have antiinflammatory and analgesic properties with less or no gastrointestinal or other NSAIDs-typical adverse effects. rofecoxib 116-125 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88 11433185-8 2001 These protective and hyperemic effects of standard preconditioning, lasted up to 6-8 h, and were significantly attenuated by pretreatment with specific COX-1 and COX-2 inhibitors such as Vioxx (5 mg/kg i.g.) rofecoxib 187-192 mitochondrially encoded cytochrome c oxidase II Homo sapiens 162-167 11405384-1 2001 This 6-week study was conducted to test the efficacy, safety, and tolerability of rofecoxib (a selective COX-2 inhibitor) compared to nabumetone (a non-selective NSAID) and placebo in osteoarthritis (OA) patients aged 80 and older. rofecoxib 82-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 105-110 11413920-0 2001 [The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%]. rofecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 11318071-5 2001 CONCLUSIONS: The safety and efficacy of two COX-2-selective inhibitors, rofecoxib and celecoxib, have been examined in a number of clinical trials, and these agents have been shown to offer efficacy similar to that of NSAIDs. rofecoxib 72-81 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 11307498-4 2001 PROMISING PERSPECTIVES: COX-2 specific inhibitors, for example cerecoxib or rofecoxib, are potentially interesting for human therapy for chemoprevention of epithelial cancer or as medical treatment, alone or in combination with other anticancer treatments. rofecoxib 76-85 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 11266647-3 2001 Indeed, development of the new "super aspirins," such as Celebrex and Vioxx, that selectively inhibit the inducible COX-2, expressed in areas of inflammation, is a direct outgrowth of this concept. rofecoxib 70-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 116-121 11231941-9 2001 Naproxen also significantly inhibited both serum TXB2 by 94% and LPS-induced PGE2 production by 77% (both P < or = 0.002 vs. placebo), but rofecoxib only inhibited COX-2-dependent LPS-induced PGE(2) (by 79%; P < 0.001 vs. placebo). rofecoxib 142-151 mitochondrially encoded cytochrome c oxidase II Homo sapiens 167-172 11032962-5 2000 Available experimental and clinical data of selective COX-2 inhibitors, including flosulide, celecoxib or rofecoxib, suggest improved gastric tolerance as compared to conventional, non-selective NSAIDs. rofecoxib 106-115 mitochondrially encoded cytochrome c oxidase II Homo sapiens 54-59 11128651-1 2000 Metabolites of the COX-2 inhibitor rofecoxib (MK-0966, Vioxx) were prepared by synthetic or biosynthetic methods. rofecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 19-24 11128651-1 2000 Metabolites of the COX-2 inhibitor rofecoxib (MK-0966, Vioxx) were prepared by synthetic or biosynthetic methods. rofecoxib 46-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 19-24 11128651-1 2000 Metabolites of the COX-2 inhibitor rofecoxib (MK-0966, Vioxx) were prepared by synthetic or biosynthetic methods. rofecoxib 55-60 mitochondrially encoded cytochrome c oxidase II Homo sapiens 19-24 11151817-10 2000 The present review assesses concept and molecular mechanism underlying specific COX-2 inhibition as well as indications, pharmakokinetics and unwanted side effects of the recently approved specific COX-2 inhibitors celecoxib and rofecoxib. rofecoxib 229-238 mitochondrially encoded cytochrome c oxidase II Homo sapiens 198-203 11231941-1 2001 BACKGROUND & AIMS: Rofecoxib, an inhibitor of the inducible cyclooxygenase (COX)-2 enzyme, appears not to cause acute gastroduodenal injury or chronic ulceration. rofecoxib 23-32 mitochondrially encoded cytochrome c oxidase II Homo sapiens 64-86 11275626-7 2001 This assertion is borne out by recent clinical studies showing that the COX-2 inhibitors rofecoxib and celecoxib procedure qualitative changes in urinary prostaglandin excretion, glomerular filtration rate, sodium retention, and their consequences similar to nonselective NSAIDs. rofecoxib 89-98 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 11398914-1 2001 Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 25-48 11398914-2 2001 Rofecoxib has greater selectivity for COX-2 than celecoxib, meloxicam, diclofenac and indomethacin. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 11478355-1 2001 The discovery of two cyclooxygenase isozymes, constitutive COX-1 and inducible COX-2, has resulted in the rapid development of selective inhibitors of COX-2, such as celecoxib and rofecoxib. rofecoxib 180-189 mitochondrially encoded cytochrome c oxidase II Homo sapiens 79-84 11478355-1 2001 The discovery of two cyclooxygenase isozymes, constitutive COX-1 and inducible COX-2, has resulted in the rapid development of selective inhibitors of COX-2, such as celecoxib and rofecoxib. rofecoxib 180-189 mitochondrially encoded cytochrome c oxidase II Homo sapiens 151-156 11590304-0 2001 Rofecoxib: a new selective COX-2 inhibitor. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 11028250-8 2000 These data support the contention that rofecoxib is the only drug of the regimens tested that uniquely inhibits COX-2 without affecting COX-1. rofecoxib 39-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 112-117 11078056-8 2000 Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1. rofecoxib 73-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 11078056-8 2000 Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1. rofecoxib 73-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 166-171 11078056-8 2000 Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1. rofecoxib 84-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 11078056-8 2000 Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1. rofecoxib 84-91 mitochondrially encoded cytochrome c oxidase II Homo sapiens 166-171 11028250-0 2000 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. rofecoxib 35-44 mitochondrially encoded cytochrome c oxidase II Homo sapiens 96-101 11028250-1 2000 Steady-state inhibitory activity of rofecoxib (Vioxx) on COX-2 versus COX-1 was compared with that of commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) in 76 healthy volunteers randomized to placebo, rofecoxib 12.5 mg qd, rofecoxib 25 mg qd, diclofenac 50 mg tid, ibuprofen 800 mg tid, sodium naproxen 550 mg bid, or meloxicam 15 mg qd. rofecoxib 36-45 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 11138599-4 2000 [symbol: see text]Rofecoxib (Vioxx--MSD) and [symbol: see text]celecoxib (Celebrex--Searle) have been developed as selective inhibitors of COX-2. rofecoxib 18-27 mitochondrially encoded cytochrome c oxidase II Homo sapiens 139-144 11138599-4 2000 [symbol: see text]Rofecoxib (Vioxx--MSD) and [symbol: see text]celecoxib (Celebrex--Searle) have been developed as selective inhibitors of COX-2. rofecoxib 29-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 139-144 11138599-6 2000 The manufacturer claims that "in clinical studies rofecoxib inhibits COX-2 but not COX-1", has "the power of high-dose NSAIDs--diclofenac and ibuprofen" and "superior GI safety profile compared to conventional NSAIDs". rofecoxib 50-59 mitochondrially encoded cytochrome c oxidase II Homo sapiens 69-74 11043057-0 2000 [Rofecoxib, a new NSAID preparation with selective COX-2 inhibition]. rofecoxib 1-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 51-56 11028250-1 2000 Steady-state inhibitory activity of rofecoxib (Vioxx) on COX-2 versus COX-1 was compared with that of commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) in 76 healthy volunteers randomized to placebo, rofecoxib 12.5 mg qd, rofecoxib 25 mg qd, diclofenac 50 mg tid, ibuprofen 800 mg tid, sodium naproxen 550 mg bid, or meloxicam 15 mg qd. rofecoxib 47-52 mitochondrially encoded cytochrome c oxidase II Homo sapiens 57-62 11043057-6 2000 A new NSAID, rofecoxib, has selective COX-2 inhibition defined as inhibition of COX-2, but not COX-1 in the therapeutic dose range. rofecoxib 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 11043057-6 2000 A new NSAID, rofecoxib, has selective COX-2 inhibition defined as inhibition of COX-2, but not COX-1 in the therapeutic dose range. rofecoxib 13-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 80-85 10877734-4 2000 OBJECTIVE: To determine the effect of rofecoxib, a member of the coxib class of drugs and a specific inhibitor of the COX-2 enzyme, on renal function in elderly patients. rofecoxib 38-47 mitochondrially encoded cytochrome c oxidase II Homo sapiens 118-123 11005360-3 2000 Two NSAIDs (celecoxib and rofecoxib) with very high specificity for COX-2 and virtually no activity against COX-1 at therapeutic doses have been approved for clinical use. rofecoxib 26-35 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-73 12024624-2 2000 Clinical studies thus far have established that the selective COX-2 inhibitors, celecoxib (Celebrex) and rofecoxib (Vioxx) are effective in the treatment of OA and RA, as are conventional NSAIDs. rofecoxib 105-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 10914695-11 2000 Two medications that predominantly inhibit only COX-2, rofecoxib and celecoxib, are currently available by prescription in the United States. rofecoxib 55-64 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 12024624-2 2000 Clinical studies thus far have established that the selective COX-2 inhibitors, celecoxib (Celebrex) and rofecoxib (Vioxx) are effective in the treatment of OA and RA, as are conventional NSAIDs. rofecoxib 116-121 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 10871971-0 2000 A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. rofecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 59-64 11014111-3 2000 Rofecoxib (Vioxx, Merck Sharp & Dohme) is a potent and selective inhibitor of the COX-2 isoform of cyclooxygenase which is used as a nonsteroidal anti-inflammatory drug (NSAID). rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 86-91 11014111-3 2000 Rofecoxib (Vioxx, Merck Sharp & Dohme) is a potent and selective inhibitor of the COX-2 isoform of cyclooxygenase which is used as a nonsteroidal anti-inflammatory drug (NSAID). rofecoxib 11-16 mitochondrially encoded cytochrome c oxidase II Homo sapiens 86-91 10871971-4 2000 Therefore, we compared the efficacy and safety of the rofecoxib, which specifically inhibits COX-2, with those of the NSAID ibuprofen in patients with OA. rofecoxib 54-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 93-98 10701410-8 2000 CURRENT TRIALS: Clinical studies focusing on both the prevention and the slowing down of early AD are under way with two recently launched selective COX-2 inhibitors, celecoxib and rofecoxib. rofecoxib 181-190 mitochondrially encoded cytochrome c oxidase II Homo sapiens 149-154 10882157-7 2000 Two drugs that are claimed to be highly selective or specific in their ability to inhibit COX-2, rofecoxib and celecoxib, are now available on prescription in the US and rofecoxib is available in Europe. rofecoxib 97-106 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 10882157-7 2000 Two drugs that are claimed to be highly selective or specific in their ability to inhibit COX-2, rofecoxib and celecoxib, are now available on prescription in the US and rofecoxib is available in Europe. rofecoxib 170-179 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 10877012-3 2000 The purpose of this study was to evaluate steady-state pharmacokinetics, biochemical selectivity and tolerability of rofecoxib (Vioxx), characterized in vitro as a COX-2 inhibitor. rofecoxib 117-126 mitochondrially encoded cytochrome c oxidase II Homo sapiens 164-169 10877012-3 2000 The purpose of this study was to evaluate steady-state pharmacokinetics, biochemical selectivity and tolerability of rofecoxib (Vioxx), characterized in vitro as a COX-2 inhibitor. rofecoxib 128-133 mitochondrially encoded cytochrome c oxidase II Homo sapiens 164-169 10877012-11 2000 CONCLUSION: The results indicate that rofecoxib is a potent and specific inhibitor of COX-2 in humans even at doses more than tenfold higher than those associated with efficacy in patients with osteoarthritis. rofecoxib 38-47 mitochondrially encoded cytochrome c oxidase II Homo sapiens 86-91 10566565-4 1999 This 8-week, double-masked, placebo-controlled trial was undertaken to assess the safety profile, tolerability, and effective dose range of once-daily rofecoxib, a COX-2-specific inhibitor, in the treatment of rheumatoid arthritis (RA). rofecoxib 151-160 mitochondrially encoded cytochrome c oxidase II Homo sapiens 164-169 11055820-6 2000 The two recently developed and clinically available selective COX-2 inhibitors, celecoxib and rofecoxib, are about 100-1000 times more selective on the COX-2 than on the COX-1 isoform. rofecoxib 94-103 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 11055820-6 2000 The two recently developed and clinically available selective COX-2 inhibitors, celecoxib and rofecoxib, are about 100-1000 times more selective on the COX-2 than on the COX-1 isoform. rofecoxib 94-103 mitochondrially encoded cytochrome c oxidase II Homo sapiens 152-157 10580458-2 1999 Rofecoxib specifically inhibits COX-2 and has demonstrated a low potential for causing upper GI injury. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 32-37 11199547-0 2000 The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex). rofecoxib 26-35 mitochondrially encoded cytochrome c oxidase II Homo sapiens 8-13 11199547-0 2000 The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex). rofecoxib 37-42 mitochondrially encoded cytochrome c oxidase II Homo sapiens 8-13 11213386-5 2000 Recently, highly selective COX-2 inhibitors have been developed such as celecoxib (Celebrex) and rofecoxib (Vioxx). rofecoxib 97-106 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 11213386-5 2000 Recently, highly selective COX-2 inhibitors have been developed such as celecoxib (Celebrex) and rofecoxib (Vioxx). rofecoxib 108-113 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 10859997-2 2000 Selective COX-2 inhibitors (i.e. celecoxib, rofecoxib) have demonstrated in clinical trials better gastrointestinal tolerability but their safety in patients with active ulcer, cardiovascular or renal disease has still to be further investigated. rofecoxib 44-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 10692773-7 1999 Another COX-2 agent--rofecoxib--is on the brink of being released. rofecoxib 21-30 mitochondrially encoded cytochrome c oxidase II Homo sapiens 8-13 10414247-5 1999 CLINICAL RESULTS: Celecoxib and rofecoxib are two COX-2 specific inhibitors. rofecoxib 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 50-55 10411562-5 1999 Rofecoxib is a time-dependent inhibitor of purified human recombinant COX-2 (IC(50) = 0.34 microM) but caused inhibition of purified human COX-1 in a non-time-dependent manner that could only be observed at a very low substrate concentration (IC(50) = 26 microM at 0.1 microM arachidonic acid concentration). rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 10411562-6 1999 In an in vitro human whole blood assay, rofecoxib selectively inhibited lipopolysaccharide-induced, COX-2-derived PGE(2) synthesis with an IC(50) value of 0.53 +/- 0.02 microM compared with an IC(50) value of 18.8 +/- 0.9 microM for the inhibition of COX-1-derived thromboxane B(2) synthesis after blood coagulation. rofecoxib 40-49 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 10411562-11 1999 Rofecoxib is a novel COX-2 inhibitor with a biochemical and pharmacological profile clearly distinct from that of current nonsteroidal anti-inflammatory drugs and represents a new therapeutic class of anti-inflammatory agents for the treatment of the symptoms of osteoarthritis and rheumatoid arthritis with improved gastrointestinal tolerability. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 10377455-5 1999 These comparisons of the actions of >40 NSAIDs and novel COX-2-selective agents, including celecoxib, rofecoxib and diisopropyl fluorophosphate, demonstrate a distribution of compound selectivities toward COX-1 that aligns with the risk of serious gastrointestinal complications. rofecoxib 105-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 10500058-3 1999 We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor. rofecoxib 52-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 10411562-3 1999 In the present study, the preclinical pharmacological and biochemical profiles of rofecoxib [Vioxx, also known as MK-0966, 4-(4"-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone], an orally active COX-2 inhibitor, are described. rofecoxib 93-98 mitochondrially encoded cytochrome c oxidase II Homo sapiens 195-200 10411562-4 1999 Rofecoxib is a potent inhibitor of the COX-2-dependent production of PGE(2) in human osteosarcoma cells (IC(50) = 26 +/- 10 nM) and Chinese hamster ovary cells expressing human COX-2 (IC(50) = 18 +/- 7 nM) with a 1000-fold selectivity for the inhibition of COX-2 compared with the inhibition of COX-1 activity (IC(50) > 50 microM in U937 cells and IC(50) > 15 microM in Chinese hamster ovary cells expressing human COX-1). rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 39-44 10411562-4 1999 Rofecoxib is a potent inhibitor of the COX-2-dependent production of PGE(2) in human osteosarcoma cells (IC(50) = 26 +/- 10 nM) and Chinese hamster ovary cells expressing human COX-2 (IC(50) = 18 +/- 7 nM) with a 1000-fold selectivity for the inhibition of COX-2 compared with the inhibition of COX-1 activity (IC(50) > 50 microM in U937 cells and IC(50) > 15 microM in Chinese hamster ovary cells expressing human COX-1). rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 177-182 10411562-4 1999 Rofecoxib is a potent inhibitor of the COX-2-dependent production of PGE(2) in human osteosarcoma cells (IC(50) = 26 +/- 10 nM) and Chinese hamster ovary cells expressing human COX-2 (IC(50) = 18 +/- 7 nM) with a 1000-fold selectivity for the inhibition of COX-2 compared with the inhibition of COX-1 activity (IC(50) > 50 microM in U937 cells and IC(50) > 15 microM in Chinese hamster ovary cells expressing human COX-1). rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 177-182 10406640-1 1999 The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. rofecoxib 37-46 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 10406640-1 1999 The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. rofecoxib 48-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 10406640-1 1999 The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. rofecoxib 56-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 10383505-1 1999 BACKGROUND: Compared with currently available NSAIDs (which inhibit COX-1 and COX-2 isoforms of cyclooxygenase), MK-0966 (a specific COX-2 inhibitor) is expected to cause less gastrointestinal toxicity. rofecoxib 113-120 mitochondrially encoded cytochrome c oxidase II Homo sapiens 133-138 10093892-4 1999 Meanwhile, the specific COX-2 inhibitors celecoxib and rofecoxib are being tested worldwide in phase III clinical trials on patients with rheumatoid arthritis and osteoarthritis. rofecoxib 55-64 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 10391671-3 1999 The role of COX-2 in the genesis of fever in monkeys and humans was examined with use of the specific COX-2 inhibitor rofecoxib. rofecoxib 118-127 mitochondrially encoded cytochrome c oxidase II Homo sapiens 102-107 10391671-10 1999 Specific inhibition of COX-2 by rofecoxib results in antipyretic activity in monkeys and humans comparable to dual COX-1/COX-2 inhibitors such as diclofenac or ibuprofen. rofecoxib 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 10096266-6 1999 RESULTS: Rofecoxib showed a >800-fold COX-2 selectivity with use of CHO cells that express human COX-1 and COX-2. rofecoxib 9-18 mitochondrially encoded cytochrome c oxidase II Homo sapiens 110-115 10391112-4 1999 Finally, the latest published clinical data of new selective and highly selective inhibitors of COX-2 (meloxicam, nimesulide, etodolac, celecoxib and MK966) are discussed. rofecoxib 150-155 mitochondrially encoded cytochrome c oxidase II Homo sapiens 96-101 10215647-2 1999 The present study was undertaken to assess the renal effects of the specific Cox-2 inhibitor, MK-966. rofecoxib 94-100 mitochondrially encoded cytochrome c oxidase II Homo sapiens 77-82 10215647-12 1999 Selective inhibition of Cox-2 by MK-966 caused a clinically insignificant and transient retention of sodium, but no depression of GFR. rofecoxib 33-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 29928230-4 2018 Rofecoxib is a prescription COX-2 selective Non-Steroidal Anti-Inflammatory Drugs (NSAID) approved in 1999. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 28-33 31534549-10 2019 We retrospectively analyzed the 5mC content of 42 patients with intestinal metaplasia (a precancerous lesion of GC) treated with a COX-2 specific inhibitor Rofecoxib or placebo for 2 years, revealing that the COX-2 inhibitor significantly down-regulated 5mC levels (N=42, P=0.009). rofecoxib 156-165 mitochondrially encoded cytochrome c oxidase II Homo sapiens 131-136 30195234-6 2018 This result was confirmed by molecular docking, which showed that these four natural lead-compounds adopt the same orientation as Rofecoxib in the COX-2 active site. rofecoxib 130-139 mitochondrially encoded cytochrome c oxidase II Homo sapiens 147-152 29732985-9 2018 The optimal pharmacologic treatment for chronic articular pain in these patients is paracetamol and COX-2 inhibitors (celecoxib and rofecoxib). rofecoxib 132-141 mitochondrially encoded cytochrome c oxidase II Homo sapiens 100-105 27388291-5 2017 To illustrate the utility of our approach, we re-analyze individual participant data from 29 randomized placebo-controlled studies on the cardiovascular risk of Vioxx, a Cox-2 selective nonsteroidal anti-inflammatory drug approved by the FDA in 1999 for the management of pain and withdrawn from the market in 2004. rofecoxib 161-166 mitochondrially encoded cytochrome c oxidase II Homo sapiens 170-175 26982261-3 2017 Celecoxib, rofecoxib, and valdecoxib are well-known specific COX-2 inhibiting drugs. rofecoxib 11-20 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-66 28375409-1 2017 The Vioxx Gastrointestinal Outcomes Research (VIGOR) trial, published in 2000, was the first to raise concerns that NSAIDs (specifically, the COX-2 selective inhibitor rofecoxib) might be associated with a higher risk for cardiovascular (CV) events. rofecoxib 4-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 142-147 28375409-1 2017 The Vioxx Gastrointestinal Outcomes Research (VIGOR) trial, published in 2000, was the first to raise concerns that NSAIDs (specifically, the COX-2 selective inhibitor rofecoxib) might be associated with a higher risk for cardiovascular (CV) events. rofecoxib 168-177 mitochondrially encoded cytochrome c oxidase II Homo sapiens 142-147 27537326-6 2016 Increasing COX-2 drug selectivity, as for rofecoxib, valdecoxib, parecoxib, and lumiracoxib, has been associated with higher cardiovascular risk, as well as dermatological and serious hepatic reactions. rofecoxib 42-51 mitochondrially encoded cytochrome c oxidase II Homo sapiens 11-16 28105626-11 2017 After rofecoxib (a COX-2 specific inhibitor) inhibited the expression of COX-2, the expression level of PGE2 was significantly decreased in a dose-dependent manner. rofecoxib 6-15 mitochondrially encoded cytochrome c oxidase II Homo sapiens 19-24 28105626-11 2017 After rofecoxib (a COX-2 specific inhibitor) inhibited the expression of COX-2, the expression level of PGE2 was significantly decreased in a dose-dependent manner. rofecoxib 6-15 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-78 25408841-2 2014 Deletion of the SO2CH3 group of rofecoxib switches the compound from a COX-2- to a COX-1-selective inhibitor, providing a 3,4-diarylfuran-2(5H)-one scaffold for structure-activity relationship studies of COX-1 inhibition. rofecoxib 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 27324742-3 2016 METHODS: A series of 3-arylidene-5-(naphthalene-2-yl)-furan-2(3H)-ones (2a-j) were synthesized by incorporating pharmacophore of COX-2 inhibitor rofecoxib and naphthyl ring of naproxen as potential non steroidal anti-inflammatory agents. rofecoxib 145-154 mitochondrially encoded cytochrome c oxidase II Homo sapiens 129-134 25806762-1 2015 BACKGROUND: The selective cyclooxygenase (COX)-2 inhibitor rofecoxib was withdrawn from the market in 2004 due to cardiovascular toxicity. rofecoxib 59-68 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-48 25559449-6 2014 The IC50 values of celecoxib, rofecoxib, sinomenine, bulleyaconitine A, tetrandrine, fangchinoline, berberine hydrochloride and sophocarpidine towards COX-2 were determined. rofecoxib 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 151-156 23454135-1 2013 Selective COX-2 inhibitors (COXib) belonging to the class of diaryl heterocycles (e.g., celecoxib, rofecoxib, etc. rofecoxib 99-108 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 24365321-21 2014 Selective inhibition of COX-2 by drugs such as rofecoxib (Vioxx) and valdecoxib (Bextra) results in specific inhibition of synthesis of prostaglandins participating in inflammation and was found to lead to vascular complications including an increased risk for stroke. rofecoxib 47-56 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 24365321-21 2014 Selective inhibition of COX-2 by drugs such as rofecoxib (Vioxx) and valdecoxib (Bextra) results in specific inhibition of synthesis of prostaglandins participating in inflammation and was found to lead to vascular complications including an increased risk for stroke. rofecoxib 58-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 23580446-4 2013 Platelet-induced COX-2-dependent prostaglandin E2 (PGE2) synthesis in HT29 cells was involved in the downregulation of p21(WAF1/CIP1) and the upregulation of cyclinB1 since these effects were prevented by rofecoxib (a selective COX-2 inhibitor) and rescued by exogenous PGE2. rofecoxib 205-214 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-22 23441769-1 2013 BACKGROUND: Cyclo-oxygenase (COX)-2 inhibitors have been the target of severe criticism, more so following the withdrawal of Rofecoxib. rofecoxib 125-134 mitochondrially encoded cytochrome c oxidase II Homo sapiens 12-35 23031659-8 2013 COX-2 inhibitors were well tolerated in the majority of the patients [nimesulide: 91.9%; meloxicam: 90.2%; rofecoxib: 94.9%; and celecoxib: 94.9%)]. rofecoxib 107-116 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 21507199-12 2012 The selective COX-2 inhibitor rofecoxib showed ability to alter the cytokine balance by affecting regulation of T-bet and GATA-3 transcription factors. rofecoxib 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 22819703-4 2012 However, synthetic NSAIDs are less potent than steroids, have limited formulation flexibility and have their own safety issues, thereby yielding unsatisfactory results, with some high-profile drugs (e.g., the COX-2 inhibitors Vioxx, Celebrex) being withdrawn from the market due to safety concerns. rofecoxib 226-231 mitochondrially encoded cytochrome c oxidase II Homo sapiens 209-214 22002318-1 2012 Rofecoxib is a specific COX-2 inhibitor able to exert antiproliferative activity against colorectal cancer cells. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 22002318-8 2012 In particular, the rofecoxib analogue retained similar potencies with respect to COX-2 inhibition but was much more active than rofecoxib in inhibiting the growth of human colon cancer cells in vitro. rofecoxib 19-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 81-86 20692174-3 2010 Among the 1H-pyrazole derivatives, 11b was found to be a potent COX-2 inhibitor, about 38 times more potent than Rofecoxib (COX-2 IC(50)=0.011 microM and 0.398 microM, respectively), but showed no selectivity for COX-2 isoform. rofecoxib 113-122 mitochondrially encoded cytochrome c oxidase II Homo sapiens 64-69 21830840-15 2011 In due course, the contrasts between DDDs of COX-2 inhibitors and non-selective NSAIDs converged, both in rofecoxib and celecoxib RCTs; therefore, doses have become more comparable in recent years because of differences in steepness of two decreasing dose trends in the case of celecoxib, and opposing dose trends in the case of rofecoxib. rofecoxib 106-115 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 21752640-2 2011 Interesting data have been obtained for 2a, which shows a selective COX-2 inhibition (albeit not as strong as Vioxx itself) exhibiting reduced hERG activity compare to the parent sulfone Vioxx (1). rofecoxib 187-192 mitochondrially encoded cytochrome c oxidase II Homo sapiens 68-73 21548865-12 2011 Suppression of COX-2 activity by selective COX-2 inhibitors such as rofecoxib or celecoxib was shown to abolish the production of ATL and to diminish the gastric tolerability of ASA and gastric adaptation developed in response to repetitive administration of this NSAID. rofecoxib 68-77 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 21548865-12 2011 Suppression of COX-2 activity by selective COX-2 inhibitors such as rofecoxib or celecoxib was shown to abolish the production of ATL and to diminish the gastric tolerability of ASA and gastric adaptation developed in response to repetitive administration of this NSAID. rofecoxib 68-77 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 24825998-1 2010 Rofecoxib is a selective cyclooxygenase COX-2 enzyme inhibitor with chemoprotective effect against cancer in experimental models. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 24825998-7 2010 It is concluded that rofecoxib offered protection against copper ions or UVB induced-DNA damage via different mechanisms not related to the inhibition COX-2. rofecoxib 21-30 mitochondrially encoded cytochrome c oxidase II Homo sapiens 151-156 22114865-0 2011 An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect? rofecoxib 73-78 mitochondrially encoded cytochrome c oxidase II Homo sapiens 46-51 22114865-3 2011 The overall objective of this paper was to examine the impact of this discrediting event on dispensing of the COX-2 class of medicines, by describing medicine switching behaviours of older Australian women using rofecoxib in September 2004; the uptake of other COX-2s; and the characteristics of women who continued using a COX-2. rofecoxib 212-221 mitochondrially encoded cytochrome c oxidase II Homo sapiens 110-115 22114865-11 2011 Continuous rofecoxib users overwhelmingly switched to another COX-2 and remained continuing COX-2 users for at least 100 days post-switch. rofecoxib 11-20 mitochondrially encoded cytochrome c oxidase II Homo sapiens 62-67 22114865-11 2011 Continuous rofecoxib users overwhelmingly switched to another COX-2 and remained continuing COX-2 users for at least 100 days post-switch. rofecoxib 11-20 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-97 24250402-7 2011 However, the recent market removal of some COXIBs such as rofecoxib due to its adverse cardiovascular side effects clearly encourages the researchers to explore and evaluate alternative templates with COX-2 inhibitory activity. rofecoxib 58-67 mitochondrially encoded cytochrome c oxidase II Homo sapiens 201-206 21600026-5 2011 RESULTS: Applying the model in a retrospective real-world scenario identified that the majority of the sample group of Australian patients aged 65 years and over with the target morbidity of the newly released COX-2-selective NSAID rofecoxib also suffered from a major morbidity excluded in the trials of that drug, indicating a substantial potential risk of adverse events amongst those patients. rofecoxib 232-241 mitochondrially encoded cytochrome c oxidase II Homo sapiens 210-215 20569079-5 2010 However, the selective COX-2 inhibitor rofecoxib was withdrawn from the market in 2004 after studies had documented an increased risk of myocardial infarction related to this drug. rofecoxib 39-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 20692174-3 2010 Among the 1H-pyrazole derivatives, 11b was found to be a potent COX-2 inhibitor, about 38 times more potent than Rofecoxib (COX-2 IC(50)=0.011 microM and 0.398 microM, respectively), but showed no selectivity for COX-2 isoform. rofecoxib 113-122 mitochondrially encoded cytochrome c oxidase II Homo sapiens 124-129 20692174-3 2010 Among the 1H-pyrazole derivatives, 11b was found to be a potent COX-2 inhibitor, about 38 times more potent than Rofecoxib (COX-2 IC(50)=0.011 microM and 0.398 microM, respectively), but showed no selectivity for COX-2 isoform. rofecoxib 113-122 mitochondrially encoded cytochrome c oxidase II Homo sapiens 124-129 18690976-1 2008 The withdrawal of the celebrity arthritis drug, rofecoxib (Vioxx) has sparked an intense discussion and controversy about the safety of the selective COX-2 inhibitors. rofecoxib 59-64 mitochondrially encoded cytochrome c oxidase II Homo sapiens 150-155 21373319-9 2010 Non-steroidal analgesics and other COX-2 inhibitors (rofecoxib and celecoxib) have been known to precipitate renal failure and hyperkalemia specially in patients at risk for the same; although not unexpected, this may be the first reported case of life-threatening hyperkalemia precipitated by etoricoxib in a previously stable patient having increased risk of renal failure and hyperkalemia. rofecoxib 53-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-40 19530988-3 2009 Attempts to identify selective inhibitors of COX-2, led to the identification of celecoxib and rofecoxib. rofecoxib 95-104 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 19374865-9 2009 We also demonstrate for the first time that the COX-2 inhibitor rofecoxib can reduce 6-keto PGF1alpha production by both enzymatic inhibition and transcriptional repression. rofecoxib 64-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 19075637-8 2008 This provided the rationale to target cox-2 enzyme and development of cox-2 selective drugs such as Vioxx and Celebrex. rofecoxib 100-105 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 19075637-8 2008 This provided the rationale to target cox-2 enzyme and development of cox-2 selective drugs such as Vioxx and Celebrex. rofecoxib 100-105 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 18802217-2 2008 This may hold true for other systems because long term use of selective COX-2 inhibitors such as VIOXX and BEXTRA was associated with heart failure, leading to their withdrawal. rofecoxib 97-102 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 20046772-1 2008 Rofecoxib, a practically insoluble cox-2 selective nonsteroidal antiinflammatory agent was subjected to improvement in solubility by preparing its binary mixtures with beta cyclodextrin using various methods such as physical mixing, co-grinding, kneading with aqueous methanol and co-evaporation from methanol-water mixture. rofecoxib 0-9 mitochondrially encoded cytochrome c oxidase II Homo sapiens 35-40 18163459-5 2008 On the other hand even a high concentration of the COX-2 specific inhibitor rofecoxib (500 microM) did not inhibit growth of SW480 cells. rofecoxib 76-85 mitochondrially encoded cytochrome c oxidase II Homo sapiens 51-56 18507001-7 2008 COX-2 inhibitors, etodolac and rofecoxib, did not have an inhibitory effect on the proliferation of LM-H3 cells at low concentrations, but had significant inhibitory effect on the invasion of LM-H3 cells in in vitro experiments. rofecoxib 31-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 18690976-1 2008 The withdrawal of the celebrity arthritis drug, rofecoxib (Vioxx) has sparked an intense discussion and controversy about the safety of the selective COX-2 inhibitors. rofecoxib 48-57 mitochondrially encoded cytochrome c oxidase II Homo sapiens 150-155 20166930-6 2010 Observation of increased cardiovascular risks in APPROVe (Adenomatous Polyp Prevention on Vioxx) study sent tremors and led to voluntary withdrawn of Vioxx (rofecoxib) by Merck from the market in September 2004 followed by Bextra (valdecoxib) in 2005 raising a question on the safety of selective COX-2 inhibitors. rofecoxib 150-155 mitochondrially encoded cytochrome c oxidase II Homo sapiens 297-302 18606461-3 2008 This has continued with the suspension of the sale of the COX-2 inhibitors rofecoxib, valdecoxib and lumiracoxib, whereas others (e.g. celecoxib and etoricoxib) are still available. rofecoxib 75-84 mitochondrially encoded cytochrome c oxidase II Homo sapiens 58-63 18541831-10 2008 For individual NSAIDs, current use of the nonselective naproxen (HR, 2.63; 95% CI, 1.47-4.72) and the COX-2-selective rofecoxib (HR, 3.38; 95% CI, 1.48-7.74) was associated with a greater risk of stroke. rofecoxib 118-127 mitochondrially encoded cytochrome c oxidase II Homo sapiens 102-107 17906610-1 2007 Following the withdrawal of rofecoxib and valdecoxib, the discussion concerning selective cyclo-oxygenase (COX)-2 inhibitors was often characterized more by emotions than scientific evidence. rofecoxib 28-37 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-113 17963198-0 2008 Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. rofecoxib 77-86 mitochondrially encoded cytochrome c oxidase II Homo sapiens 50-55 17387473-2 2007 EXPERIMENTAL DESIGN: Patients with squamous cell carcinoma of the head and neck preoperatively received a specific COX-2 inhibitor (rofecoxib, 25 mg daily) orally for 3 weeks. rofecoxib 132-141 mitochondrially encoded cytochrome c oxidase II Homo sapiens 115-120 18473007-2 2007 In recent years concerns have arisen about the cardiovascular safety of these drugs, initially because of reported associations between therapy with the COX-2 selective inhibitor rofecoxib and myocardial infarction. rofecoxib 179-188 mitochondrially encoded cytochrome c oxidase II Homo sapiens 153-158 17661262-1 2007 Concerning the current discussion about cardiovascular toxicity of the selective COX-2 inhibitors, recently advertised in the media as a new milestone in the management of pain, culminating in the market withdrawal of the preparations Vioxx (rofecoxib) in 2004 and Bextra (valdecoxib) in 2005, the classical NSAIDs are now spotlighted. rofecoxib 235-240 mitochondrially encoded cytochrome c oxidase II Homo sapiens 81-86 17786211-6 2007 Trends in inpatient stay due to MI were tightly coupled to the rise and fall of prescriptions of COX-2 inhibitors, with an 18.5% increase in inpatient stays for MI when both rofecoxib and celecoxib were on the market (P<0.001). rofecoxib 174-183 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 17880512-6 2007 In contrast, application of SC-560 and rofecoxib, specific inhibitors of COX-1 and COX-2, respectively, attenuated PDT. rofecoxib 39-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88 19804301-5 2007 His work linked COX-2 inhibitors such as Celebrex and Vioxx (Merck, NJ, USA) with heart attacks, and prevented Merck"s similar product, Arcoxia, from being approved. rofecoxib 54-59 mitochondrially encoded cytochrome c oxidase II Homo sapiens 16-21 17661262-1 2007 Concerning the current discussion about cardiovascular toxicity of the selective COX-2 inhibitors, recently advertised in the media as a new milestone in the management of pain, culminating in the market withdrawal of the preparations Vioxx (rofecoxib) in 2004 and Bextra (valdecoxib) in 2005, the classical NSAIDs are now spotlighted. rofecoxib 242-251 mitochondrially encoded cytochrome c oxidase II Homo sapiens 81-86 17316360-6 2007 This study investigated the effect of aspirin and a COX2 inhibitor (rofecoxib) on an HNPCC EC cell line model (Ishikawa) by assessing the effect on proliferation, apoptosis, the cell cycle, and MMR gene expression. rofecoxib 68-77 mitochondrially encoded cytochrome c oxidase II Homo sapiens 52-56 17878525-11 2007 By using the COX-2 inhibitors rofecoxib and nimesulide, we were able to delay tumor-mediated wasting in vivo. rofecoxib 30-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 17652824-8 2007 As a result of research focused on reduction of the adverse effects of NSAIDs, selective COX-2 inhibitors, such as celecoxib and rofecoxib have been developed. rofecoxib 129-138 mitochondrially encoded cytochrome c oxidase II Homo sapiens 89-94 17453399-2 2007 METHODS: We performed a randomized controlled study to evaluate the effect of the selective COX-2 inhibitor rofecoxib compared to that of indomethacin on the incidence and extent of heterotopic ossification in patients who had undergone hip replacement surgery. rofecoxib 108-117 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-97 17453399-9 2007 INTERPRETATION: After short-term administration, the selective COX-2 inhibitor rofecoxib was effective in preventing heterotopic ossification after total hip arthroplasty. rofecoxib 79-88 mitochondrially encoded cytochrome c oxidase II Homo sapiens 63-68 16645868-1 2007 After the oral administration of the COX 2 inhibitor rofecoxib (Vioxx) as part of an oral provocation test, a 64-year-old woman developed acute anterograde and retrograde amnesia which lasted for several hours. rofecoxib 53-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 16645868-1 2007 After the oral administration of the COX 2 inhibitor rofecoxib (Vioxx) as part of an oral provocation test, a 64-year-old woman developed acute anterograde and retrograde amnesia which lasted for several hours. rofecoxib 64-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42